1. Rapid unusual reasorbtion of drusenoid subfoveal lesions in AMD and pseudovitelliform maculopathy documented with SD-OCT and autofluorescence. Giorgio F. Pacelli MD, Vito Belloli MD, UOC oculistica, Ospedale di Arona (No).

2. daily intake of an AREDS2 formulation containing microalgale DHA e tocotrienols Case Report 1: BO 72 years old female February 2009: daily intake of an AREDS2 formulation containing microalgale DHA e tocotrienols 8 months’ follow-up 20 months’ follow-up Visus 0,9 0,1 logmar Visus 10/10 0,0 logmar

3. Baseline 8 months’ follow-up 1 & ½ year follow-up Autofluorescence evolution.

4. BO: Fellow eye evolution. 8 months’ evolution 20 months’evolution ETDRS BCVA 0.0 logm

5. Baseline 8 months’ follow-up 20 months’ evolution Autofluorescence evolution

6. daily intake of an AREDS2 formulation containing microalgale DHA e tocotrienols Case report 2 (MC): 75 years old famale areds 4 category AMD left eye daily intake of an AREDS2 formulation containing microalgale DHA e tocotrienols 8 months later 18 Months later BCVA: 0.8 dec 0.16 logm BCVA 1.0 dec 0.0 logm

7. AF evolution: baseline 8 months later 18 months later

8. (MC)_ SD-OCT Cirrus Zeiss Follow up ( RPE level scan slice )

9. BCVA 0.6 dec; 0.24 logmar +1.75 sf BCVA 0.9 dec; 0.04 logmar +0.75 sf daily intake of an AREDS2 formulation containing microalgale DHA e tocotrienols Case report 3: (BD): 80 years old male may 2009: daily intake of an AREDS2 formulation containing microalgale DHA e tocotrienols Case report 3(BD): 04-10 ( 12 months’ follow up)

10. BD: Right eye of the same patients: BCVA 1.0 12 months later BCVA 1.0

11. Case report 4 RA: AMD with RPE pattern shape abnormalities and metamorphopsia complaint in the latest 2 months: (AREDS 4 category: controlateral eyes evoluted AMD):

12. Case report 4: areds 2 formulation prescription BCVA 0.5 dec; 0,3 logmar 3 montths later: BCVA 0.8 dec) 8 months later: 0.9 dec: 0.04 logm

13. extrafoveal CNV treated directly with argon laser in a patients supplemented with AREDS1 formulation BCVA 0.9 dec; 0.06 logmar Case report 6 (BI): baseline oct 08: 3 mos later: BCVA 0.9 dec ( 0.1 log); Increment in soft drusen confluence; no more evidence of CNV

14. 05-10 BCVA 0.9 0.1 logm 08-2010 BCVA 0.9 0.04 logm 20 months later after a daily intake of an AREDS2 formulation containing ω3-microalgale & tocotrienols

15. Case report 7: Pseudovitelliform macular lesion with a subfoveal lipofusinic accumulation (BS). Daily intake of AREDS2 (tocotrienols e microalgale ω3 ): BCVA 0.8 dec ( 0.1 logmar) 6 months later: BCVA 0.9 ( 0,08 logmar)

16. BS: 15 months later: further reduction of lipofuscine.

17. Case report 7: Left eye: PV maculopathy & foveal PRC misalignement BCVA 0.8 (0.1 logmar) 6 months later: BCVA 0.9 ( 0.02 logmar)

18. 15 months later: regularization of PRC disalignament

19. MOIS 05-10

20. PV maculopathy treated with an areds1 formulation: BCVA 0.8 ( 0.1 logmar) ILM- EPR Line

21. 1 year follow up (ω3 free formulation) : BCVA 0.1 dec 1.0 logmar (!!!!) Linea ILM EPR post Linea ILM- EPR pre

24. Take home message: The evidence of SD OCT and AF evolution of these drusenoid lesions suggest the utility of AREDS-2 formulation in preventing AMD evolution, waiting for confirmatory results coming out from ongoing AREDS2 studies. Thank you for your attention